Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294112 · ClinicalTrials.gov registry record · Phase 2
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
A Phase 2 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00294112 is a Phase 2 study that has completed, run by Mesoblast. The registered enrollment target is 10 participants.
The verdict
NCT00294112, a Phase 2 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair. Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms.
Interventions
- DRUG Prochymal™ adult human mesenchymal stem cells
- DRUG adult human mesenchymal stem cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-03-13 |
| Est. Completion | 2006-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294112
The ClinicalTrials.gov registry entry for NCT00294112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prochymal™ adult human mesenchymal stem cells is the first listed.
NCT00294112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294112 about?
NCT00294112 is a clinical study titled "Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease". Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair. Prochymal™ MSCs will be...
What is the current status of trial NCT00294112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-03-13. Estimated completion is 2006-07-21.
What interventions are being tested in trial NCT00294112?
The interventions under investigation include: Prochymal™ adult human mesenchymal stem cells (DRUG), adult human mesenchymal stem cells (DRUG).
Who is sponsoring clinical trial NCT00294112?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.